BRCA1或BRCA2突变女性中避孕措施使用与卵巢癌风险
该匹配病例对照研究纳入1733对匹配女性,评估BRCA突变携带者中避孕方式与卵巢癌风险的关系。任何避孕措施曾使用与卵巢癌风险降低显著相关(OR=0.62),主要由口服避孕药(OR=0.66)和避孕植入剂(OR=0.30)驱动;注射剂呈相似趋势但未达显著(OR=0.37),宫内节育器使用模式无显著关联。
要点
- BRCA突变女性中,任何避孕措施曾使用与卵巢癌风险降低显著相关(OR=0.62)。
- 口服避孕药(OR=0.66)和避孕植入剂(OR=0.30)与卵巢癌风险降低显著相关。
- 注射剂呈相似保护趋势但未达统计学显著(OR=0.37),宫内节育器无显著关联。
核心结论
- 研究结果支持口服避孕药和避孕植入剂对BRCA突变女性卵巢癌风险具有保护作用。
- 注射剂可能的保护作用需进一步评估。
研究设计与样本
- 匹配病例对照研究,共纳入1733对匹配女性。
- 按出生年份、研究入组日期、居住国家、BRCA突变类型和乳腺癌史进行匹配。
- 通过常规问卷收集激素、生殖和生活方式暴露的详细信息。
- 采用条件logistic回归估计各避孕暴露的比值比(OR)和95%置信区间(CI)。
主要发现
- 任何避孕措施曾使用与卵巢癌风险降低显著相关(OR=0.62;95%CI 0.52-0.75;P<0.0001)。
- 口服避孕药与卵巢癌风险降低显著相关(OR=0.66;95%CI 0.54-0.79;P<0.0001)。
- 避孕植入剂与卵巢癌风险降低显著相关(OR=0.30;95%CI 0.12-0.73;P=0.008)。
- 注射剂使用呈相似效应(OR=0.37;95%CI 0.10-1.38;P=0.14),但未达统计学显著。
- 宫内节育器使用模式与卵巢癌风险之间未观察到显著关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 注射剂可能的保护作用需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background BRCA1 and BRCA2 (BRCA) mutation carriers face a high lifetime risk of developing ovarian cancer. Oral contraceptives are protective in this population; however, the impact of other types of contraception (e.g. intrauterine devices, implants, injections) is unknown. We undertook a matched case-control study to evaluate the relationship between type of contraception and risk of ovarian cancer among women with BRCA mutations. Methods A total of 1733 matched pairs were included in this analysis. Women were matched according to year of birth, date of study entry, country of residence, BRCA mutation type and history of breast cancer. Detailed information on hormonal, reproductive and lifestyle exposures were collected from a routinely administered questionnaire. Conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) associated with each contraceptive exposure. Results Ever use of any contraceptive was significantly associated with reduced risk of ovarian cancer (OR = 0.62; 95% CI 0.52-0.75; P < 0.0001), which was driven by significant inverse associations with oral contraceptives (OR = 0.66; 95% CI 0.54-0.79; P < 0.0001) and contraceptive implants (OR = 0.30; 95% CI 0.12-0.73; P = 0.008). We observed a similar effect with use of injections (OR = 0.37; 95% CI 0.10-1.38; P = 0.14), but this did not achieve significance. No significant associations were observed between patterns of intrauterine device use and risk of ovarian cancer. Conclusions These findings support a protective effect of oral contraceptives and implants on risk of ovarian cancer among women with BRCA mutations. The possible protective effect of injections requires further evaluation.
引用
- Xia YY, Gronwald J, Karlan B, et al. Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecol Oncol. 2022. PMID: 35063280. doi:10.1016/j.ygyno.2022.01.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。